Daniel Brennan
Stock Analyst at TD Cowen
(1.78)
# 3,331
Out of 5,044 analysts
20
Total ratings
33.33%
Success rate
5.21%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $5.68 | +181.69% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.32 | +89.39% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $15.11 | +91.93% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $2.09 | +19.62% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $613 → $670 | $563.78 | +18.84% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $195.28 | +2.42% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,419.71 | -45.76% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $63.50 | +81.10% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $5.68
Upside: +181.69%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.32
Upside: +89.39%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $15.11
Upside: +91.93%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $2.09
Upside: +19.62%
Thermo Fisher Scientific
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $563.78
Upside: +18.84%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $195.28
Upside: +2.42%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,419.71
Upside: -45.76%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $63.50
Upside: +81.10%